Transcriptomic Algorithm Shows Ability to Predict Progression-Free Survival
Posted: Friday, April 30, 2021
A transcriptomic algorithm can more precisely predict the extent to which cancer patients might benefit from targeted treatments or immunotherapy compared to genomic biomarkers
NEW YORK – Researchers within the Worldwide Innovative Networking (WIN) Consortium are pushing ahead with research to try to show that a transcriptomic algorithm can more precisely predict the extent to which cancer patients might benefit from targeted treatments or immunotherapy compared to genomic biomarkers.
Apr 30, 2021 Turna Ray
NEW YORK (GenomeWeb)
NEW YORK – Researchers within the Worldwide Innovative Networking (WIN) Consortium are pushing ahead with research to try to show that a transcriptomic algorithm can more precisely predict the extent to which cancer patients might benefit from targeted treatments or immunotherapy compared to genomic biomarkers.
In a paper published in NPJ Precision Oncology this week, researchers co-led by Vladimir Lazar, WIN's chief scientific and operating officer, described the development of a prototype